Perifosine: Update on a novel Akt inhibitor

Current Oncology Reports

Volumn 11, Issue 2, 2009, Pages 102-110

  Gills, Joell J ^b   Dennis, Phillip A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

17 DEMETHOXY 17 (2 DIMETHYLAMINOETHYLAMINO)GELDANAMYCIN; 7 HYDROXYSTAUROSPORINE; BORTEZOMIB; CETUXIMAB; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; ERLOTINIB; ETOPOSIDE; GEMCITABINE; HISTONE DEACETYLASE INHIBITOR; IMATINIB; LENALIDOMIDE; MELPHALAN; PACLITAXEL; PERIFOSINE; PROTEIN KINASE B; SORAFENIB; SUNITINIB; TEMOZOLOMIDE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CLINICAL TRIAL; DRUG ACCUMULATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG SELECTIVITY; DRUG TARGETING; FATIGUE; GASTROINTESTINAL SYMPTOM; HUMAN; LIPID RAFT; LOADING DRUG DOSE; MAXIMUM TOLERATED DOSE; MONOTHERAPY; NONHUMAN; PATHOPHYSIOLOGY; PHARMACODYNAMICS; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR;

ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; MEMBRANE MICRODOMAINS; NEOPLASMS; PHOSPHORYLCHOLINE; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 60349088457     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-009-0016-4     Document Type: Review

References (63)

1. Bai X, Ma D, Liu A, et al.: Rheb activates mTOR by antagonizing its endogenous inhibitor, FKBP38. Science 2007, 318:977-980.
2. LoPiccolo J, Granville CA, Gills JJ, Dennis PA: Targeting Akt in cancer therapy. Anticancer Drugs 2007, 18:861-874.
3. Catley L, Hideshima T, Chauhan D, et al.: Alkyl phospholipid perifosine induces myeloid hyperplasia in a murine myeloma model. Exp Hematol 2007, 35:1038-1046.
4. Chiarini F, Del Sole M, Mongiorgi S, et al.: The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrugresistant human T-acute leukemia cells by a JNK-dependent mechanism. Leukemia 2008, 22:1106-1116.
5. Hideshima T, Catley L, Yasui H, et al.: Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 2006, 107:4053-4062.
6. Elrod HA, Lin YD, Yue P, et al.: The alkylphospholipid perifosine induces apoptosis of human lung cancer cells requiring inhibition of Akt and activation of the extrinsic apoptotic pathway. Mol Cancer Ther 2007, 6:2029-2038.
7. Kondapaka SB, Singh SS, Dasmahapatra GP, et al.: Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol Cancer Ther 2003, 2:1093-1103.
8. Festuccia C, Gravina GL, Muzi P, et al.: Akt down-modulation induces apoptosis of human prostate cancer cells and synergizes with EGFR tyrosine kinase inhibitors. Prostate 2008, 68:965-974.
9. Floryk D, Thompson TC: Perifosine induces differentiation and cell death in prostate cancer cells. Cancer Lett 2008, 266:216-226.
10. Hideshima T, Catley L, Raje N, et al.: Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells. Br J Haematol 2007, 138:783-791.
11. Nyakern M, Cappellini A, Mantovani I, Martelli AM: Synergistic induction of apoptosis in human leukemia T cells by the Akt inhibitor perifosine and etoposide through activation of intrinsic and Fas-mediated extrinsic cell death pathways. Mol Cancer Ther 2006, 5:1559-1570.
12. Hennessy BT, Lu Y, Poradosu E, et al.: Pharmacodynamic markers of perifosine efficacy. Clin Cancer Res 2007, 13:7421-7431.
13. Momota H, Nerio E, Holland EC: Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo. Cancer Res 2005, 65:7429-7435.
14. de la Pena L, Burgan WE, Carter DJ, et al.: Inhibition of Akt by the alkylphospholipid perifosine does not enhance the radiosensitivity of human glioma cells. Mol Cancer Ther 2006, 5:1504-1510.
15. Papa V, Tazzari PL, Chiarini F, et al.: Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells. Leukemia 2008, 22:147-160.
16. Ruiter GA, Zerp SF, Bartelink H, et al.: Anti-cancer alkyl-lysophospholipids inhibit the phosphatidylinositol 3-kinase-Akt/ PKB survival pathway. Anticancer Drugs 2003, 14:167-173.
17. Li X, Luwor R, Lu Y, et al.: Enhancement of antitumor activity of the anti-EGF receptor monoclonal antibody cetuximab/C225 by perifosine in PTEN-deficient cancer cells. Oncogene 2006, 25:525-535.
18. Leleu X, Jia X, Runnels J, et al.: The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia. Blood 2007, 110:4417-4426.
19. Vinall RL, Hwa K, Ghosh P, et al.: Combination treatment of prostate cancer cell lines with bioactive soy isoflavones and perifosine causes increased growth arrest and/or apoptosis. Clin Cancer Res 2007, 13:6204-6216.
20. Huston A, Leleu X, Jia X, et al.: Targeting Akt and heat shock protein 90 produces synergistic multiple myeloma cell cytotoxicity in the bone marrow microenvironment. Clin Cancer Res 2008, 14:865-874.
21. Zhang L, Lee KC, Bhojani MS, et al.: Molecular imaging of Akt kinase activity. Nat Med 2007, 13:1114-1119.
22. Van Ummersen L, Binger K, Volkman J, et al.: A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer. Clin Cancer Res 2004, 10:7450-7456.
23. Crul M, Rosing H, de Klerk GJ, et al.: Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours. Eur J Cancer 2002, 38:1615-1621.
24. Henderson IC, Spigel DR, Nemunaitis JJ, et al.: A phase I study of weekly, divided dose perifosine in patients with non-small cell lung cancer. J Clin Oncol 2006, 24:13060.
25. Monga M, Messmann RA, Headlee D, et al.: A phase I trial of perifosine in patients with refractory neoplasms [abstract]. Proc Am Soc Clin Oncol 2002, 21:1837.
26. Stephenson J, Schreeder M, Waples J, et al.: Perifosine, active as a single agent for renal cell carcinoma, now in phase I trials combined with tyrosine kinase inhibitors. J Clin Oncol 2007, 25:15622.
27. Knowling M, Blackstein M, Tozer R, et al.: A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: A National Cancer Institute of Canada Clinical Trials Group trial. Invest New Drugs 2006, 24:435-439.
28. Bailey HH, Mahoney MR, Ettinger DS, et al.: Phase II study of daily oral perifosine in patients with advanced soft tissue sarcoma. Cancer 2006, 107:2462-2467.
29. Birch R, Chawla S, Nemunaitis J, et al.: Perifosine as an active agent in the treatment of patient with advanced sarcoma. J Clin Oncol 2007, 25(18S):10059.
30. Steinert D, Henderson C, Chawla S, et al.: A phase II trial of perifosine in patients with chemo-insensitive sarcomas-study update [abstract 860]. Presented at the 13th Annual Meeting of the Connective Tissue Oncology Society. Seattle, WA; November 1-3, 2007.
31. Ghobrial IM, Leleu X, Rubin N, et al.: Phase II trial of the novel oral Akt inhibitor perifosine in relapsed and/or refractory Waldenstrom macroglobulinemia [abstract]. J Clin Oncol 2008, 26:8546.
32. Richardson P, Lonial S, Jakubowiak A, et al.: Multi-center phase II study of perifosine alone and in combination with dexamethasone for patients with relapsed or refractory multiple myeloma: Promising activity as combination therapy with manageable toxicity [abstract]. Blood 2007, 110:1164.
33. Campos LT, Stephenson J, Swan F, et al.: Daily dose of perifosine less toxic than weekly and active in patients with hepatocellular carcinoma [abstract]. J Clin Oncol 2007, 25(18S):15072.
34. Posadas EM, Gulley J, Arlen PM, et al.: A phase II study of perifosine in androgen independent prostate cancer. Cancer Biol Ther 2005, 4:1133-1137.
35. Chee KG, Longmate J, Quinn DI, et al.: The AKT inhibitor perifosine in biochemically recurrent prostate cancer: A phase II California/ Pittsburgh cancer consortium trial. Clin Genitourin Cancer 2007, 5:433-437.
36. Leighl NB, Dent S, Clemons M, et al.: A phase 2 study of perifosine in advanced or metastatic breast cancer. Breast Cancer Res Treat 2008, 108:87-92.
37. Marsh Rde W, Rocha Lima CM, Levy DE, et al.: A phase II trial of perifosine in locally advanced, unresectable, or metastatic pancreatic adenocarcinoma. Am J Clin Oncol 2007, 30:26-31.
38. Hedley D, Moore MJ, Hirte H, et al.: A phase II trial of perifosine as a second line therapy for advanced pancreatic cancer. A study of the Princess Margaret Hospital Phase II Consortium. J Clin Oncol 2005, 23:4166.
39. Ernst DS, Eisenhauer E, Wainman N, et al.: Phase II study of perifosine in previously untreated patients with metastatic melanoma. Invest New Drugs 2005, 23:569-575.
40. Argiris A, Cohen E, Karrison T, et al.: A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer. Cancer Biol Ther 2006, 5:766-770.
41. Poradosu E, Lemmon M, Keleti D: Perifosine selectively inhibits binding of Akt PH domain to PtdIns(3,4)P2. Proceedings of the American Association for Cancer Research Annual Meeting (2007). Philadelphia: AACR; 2007:1645.
42. Arthur G, Bittman R: The inhibition of cell signaling pathways by antitumor ether lipids. Biochim Biophys Acta 1998, 1390:85-102.
43. Vink SR, Schellens JH, van Blitterswijk WJ, Verheij M: Tumor and normal tissue pharmacokinetics of perifosine, an oral anti-cancer alkylphospholipid. Invest New Drugs 2005, 23:279-286.
44. van der Luit AH, Vink SR, Klarenbeek JB, et al.: A new class of anticancer alkylphospholipids uses lipid rafts as membrane gateways to induce apoptosis in lymphoma cells Mol Cancer Ther 2007, 6:2337-2345.
45. Lasserre R, Guo XJ, Conchonaud F, et al.: Raft nanodomains contribute to Akt/PKB plasma membrane recruitment and activation. Nat Chem Biol 2008, 4:538-547.
46. Gajate C, Mollinedo F: Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts. Blood 2007, 109:711-719.
47. Rahmani M, Reese E, Dai Y, et al.: Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species. Cancer Res 2005, 65:2422-2432.
48. Vink SR, van der Luit AH, Klarenbeek JB, et al.: Lipid rafts and metabolic energy differentially determine uptake of anti-cancer alkylphospholipids in lymphoma versus carcinoma cells. Biochem Pharmacol 2007, 74:1456-1465.
49. Van der Luit AH, Budde M, Zerp S, et al.: Resistance to alkyl-lysophospholipid-induced apoptosis due to downregulated sphingomyelin synthase 1 expression with consequent sphingomyelin- and cholesterol-deficiency in lipid rafts. Biochem J 2007, 401:541-549.
50. Patel V, Lahusen T, Sy T, et al.: Perifosine, a novel alkylphospholipid, induces p21(WAF1) expression in squamous carcinoma cells through a p53-independent pathway, leading to loss in cyclin-dependent kinase activity and cell cycle arrest. Cancer Res 2002, 62:1401-1409.
51. David E, Sinha R, Chen J, et al.: Perifosine synergistically enhances TRAIL-induced myeloma cell apoptosis via up-regulation of death receptors. Clin Cancer Res 2008, 14:5090-5098.
52. Martelli AM, Papa VS, Tazzari PL, et al.: The novel Akt inhibitor perifosine induces apoptosis, cell cycle arrest and synergizes with chemotherapeutic drugs in acute myelogenous leukemia cells by a JNK dependent mechanism-a novel therapeutic approach for leukemia displaying elevated Akt signaling [abstract]. Blood (ASH Annual Meeting Abstracts) 2007, 110:3355.
53. Dasmahapatra GP, Didolkar P, Alley MC, et al.: In vitro combination treatment with perifosine and UCN-01 demonstrates synergism against prostate (PC-3) and lung (A549) epithelial adenocarcinoma cell lines. Clin Cancer Res 2004, 10:5242-5252.
54. Vink SR, Lagerwerf S, Mesman E, et al.: Radiosensitization of squamous cell carcinoma by the alkylphospholipid perifosine in cell culture and xenografts. Clin Cancer Res 2006, 12:1615-1622.
55. Vink SR, Schellens JH, Beijnen JH, et al.: Phase I and pharmacokinetic study of combined treatment with perifosine and radiation in patients with advanced solid tumours. Radiother Oncol 2006, 80:207-213.
56. Jakubowiak A, Zimmerman T, Alsina M, et al.: A multiple myeloma research consortium multicenter phase I trial of perifosine in combination with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma: Updated results [abstract]. Blood 2007, 110:1169.
57. Schreeder MT, Figlin RA, Stephenson JJ, et al.: Phase I multicenter trial of perifosine in combination with sorafenib for patients with advanced cancers including renal cell carcinoma [abstract]. J Clin Oncol 2008, 26:16024.
58. Allerton JP, Ebrahimi B, Schreeder MT, et al.: Phase I report from a multicenter trial of perifosine and sunitinib in patients with advanced cancers including renal cell carcinoma [abstract]. J Clin Oncol 2008, 26:14565.
59. Cervera A, Bernhardt B, Nemunaitis JJ, et al.: Perifosine can be combined with docetaxel without dose reduction of either drug. J Clin Oncol 2006, 24:13066.
60. Goggins TF, Nemunaitis JJ, Schiffman R, et al.: A phase I study of daily oral perifosine with every 3-week paclitaxel. J Clin Oncol 2006, 24:13134.
61. Ebrahimi B, Nemunaitis JJ, Shiffman R, et al.: A phase I study of daily oral perifosine with weekly paclitaxel [abstract]. J Clin Oncol 2006, 24:13117.
62. Weiss S, Nemunaitis JJ, Diaz-Lacayo M, et al.: A phase I study of daily oral perifosine and weekly gemcitabine [abstract]. J Clin Oncol 2006, 24:13084.
63. Richardson P, Jakubowiak A, Wolf J, et al.: Phase I/II report from a multicenter trial of perifosine and bortezomib in patients with relapsed or relapsed/refractory multiple myeloma previously treated with bortezomib [abstract]. Blood 2007, 110:1170.